Articles

Ongoing Phase 3 Randomized Trial, Beamion LUNG-2, of Zongertinib Versus Standard of Care in Patients With Advanced NSCLC Harboring HER2 TKD Mutations
Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses the trial design of Beamion LUNG-2, a randomized phase 3 trial of zongertinib versus standard of care in patients with locally advanced or metastatic NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. She discusses the role of nurses in clinical trials, including providing essential monitoring and support to patients during their trial participation. Read More ›

Data From ASCO 2024: Exposure-Response Analysis of Trastuzumab Deruxtecan to Inform Dosing in Patients With HER2-Mutated NSCLC
Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses results from an exposure-efficacy and exposure-safety analysis of trastuzumab deruxtecan in patients with HER2-mutated NSCLC. In her recap, she highlights the importance of education around dose adjustments to manage patient expectations. Read More ›

Final Results of DESTINY-Lung02 from ASCO 2024: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC
Final results from the randomized phase 2 trial of trastuzumab deruxtecan in patients with HER2-mutant NSCLC were reported at ASCO 2024 and summarized in this video by Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP. She recaps the efficacy and safety data while highlighting the importance of nurses in assessing and managing adverse events associated with these medications. Read More ›

Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path
The Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path is a resource that oncology nurses and navigators can use to assist patients and caregivers in the fight against early-stage breast cancer. Oncology nurses and navigators guide patients through their treatment journey from time of diagnosis into survivorship, providing education, resources, and support. Read More ›

Quick Quiz: Prostate Cancer Edition
According to the National Cancer Institute, prostate cancer is the most common cancer in US men and the second highest cause of cancer death in this patient population. In fact, an estimated 299,010 new cases will be diagnosed in 2024 and approximately 12.9% of men will receive this diagnosis in their lifetime. Thus, a significant portion of your patients and their loved ones will be affected by this prevalent disease. Test your knowledge now. Read More ›

The National Cancer Institute invests in a broad portfolio of research, supporting the cancer research workforce and sustaining the infrastructure that enables cutting-edge research to succeed. These efforts are essential to lead progress against cancer and accomplish the goals of the National Cancer Plan. Read More ›

On June 26, 2024, the FDA approved epcoritamab-bysp (Epkinly; Abbvie and Genmab) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after ≥2 lines of prior therapy. Read More ›

OFS Therapy Highlights
Experts provide notable points on ovarian function suppression therapy, including suitable patient populations, effective utilization, and valuable navigation approaches. Read More ›

Recognizing the complexities of treatment with oral medications is an important step toward successful outcomes. Read More ›

An addition to TACE may have the potential to set a new standard of care in unresectable HCC eligible for embolization. Read More ›

Page 9 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: